EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using plasma proteomics profiling

Heidi S Lumish iD, Nina Harano iD, Lusha W Liang iD, Kohei Hasegawa iD, Mathew S Maurer iD, Albree Tower-Rader, Michael A Fifer iD, Muredach P Reilly, Yuichi J Shimada iD

Europace · 2024

DOI: 10.1093/europace/euae267 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Europace, 2024. Verfasst von Heidi S Lumish und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 622 West 168th Street, PH3-342, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cardiomyopathy, Hypertrophic, Proteomics, Predictive Value of Tests. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Feldstein Medical Foundation, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Atrial fibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), increasing symptom burden and stroke risk. We aimed to construct a plasma proteomics-based model to predict new-onset AF in patients with HCM and determine dysregulated signalling pathways. Methods and results In this prospective, multi-centre cohort study, we conducted plasma proteomics profiling of 4986 proteins at enrolment. We developed a proteomics-based machine learning model to predict new-onset AF using samples from one institution (training set) and tested its predictive ability using independent samples from another institution (test set). We performed a survival analysis to compare the risk of new-onset AF among high- and low-risk groups in the test set. We performed pathway analysis of proteins significantly (univariable P < 0.05) associated with new-onset AF using a false discovery rate (FDR) threshold of 0.001. The study included 284 patients with HCM (training set: 193, test set: 91). Thirty-seven (13%) patients developed AF during median follow-up of 3.2 years [25–75 percentile: 1.8–5.2]. Using the proteomics-based prediction model developed in the training set, the area under the receiver operating characteristic curve was 0.89 (95% confidence interval 0.78–0.99) in the test set. In the test set, patients categorized as high risk had a higher rate of developing new-onset AF (log-rank P = 0.002). The Ras-MAPK pathway was dysregulated in patients who developed incident AF during follow-up (FDR < 1.0 × 10−6).

Conclusion

This is the first study to demonstrate the ability of plasma proteomics to predict new-onset AF in HCM and identify dysregulated signalling pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCardiomyopathy, HypertrophicProteomicsPredictive Value of TestsBiomarkersHumansFemaleMaleMiddle AgedProspective StudiesRisk AssessmentMachine LearningAdultAgedRisk FactorsBlood ProteinsSignal TransductionPrognosis

Stichwörter der Autor:innen

Atrial fibrillationHypertrophic cardiomyopathyPredictionProteomics

Substanzen

BiomarkersBlood Proteins

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 622 West 168th Street, PH3-342, New York, NY 10032, USA.
  • Department of Biology, Columbia University, New York, NY, USA.
  • Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Irving Institute for Clinical and Translational Research, Columbia University Irving Medical Center, New York, NY, USA.

ORCID-Profile: Heidi S Lumish, Nina Harano, Lusha W Liang, Kohei Hasegawa, Mathew S Maurer, Michael A Fifer, Yuichi J Shimada

Förderung

  • Feldstein Medical Foundation
  • NHLBI NIH HHS
  • NIH HHS
  • American Heart Association
  • NIA NIH HHS
  • Korea Institute of Oriental Medicine
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Lumish, H. S., Harano, N., Liang, L. W., Hasegawa, K., Maurer, M. S., Tower-Rader, A., Fifer, M. A., Reilly, M. P., & Shimada, Y. J. (2024). Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using plasma proteomics profiling. Europace. https://doi.org/10.1093/europace/euae267

Vancouver

Lumish HS, Harano N, Liang LW, Hasegawa K, Maurer MS, Tower-Rader A, et al. Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using plasma proteomics profiling. Europace. 2024. doi:10.1093/europace/euae267

BibTeX
@article{Lumish2024,
  author = {Lumish, Heidi S and Harano, Nina and Liang, Lusha W and Hasegawa, Kohei and Maurer, Mathew S and Tower-Rader, Albree and Fifer, Michael A and Reilly, Muredach P and Shimada, Yuichi J},
  title = {Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using plasma proteomics profiling},
  journal = {Europace},
  year = {2024},
  doi = {10.1093/europace/euae267}
}
Kostenlos starten →